<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3363856</article-id><article-id pub-id-type="publisher-id">cc11045</article-id><article-id pub-id-type="doi">10.1186/cc11045</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in pediatric cardiac surgery (FICCS study)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Galas</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Hajjar</surname><given-names>L</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Sorensen</surname><given-names>B</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Almeida</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Sundin</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Guimaraes</surname><given-names>V</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Zefferino</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Camara</surname><given-names>L</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Maua</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Moreira</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Puttini</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Carmona</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Auler</surname><given-names>J</given-names><suffix>Jr</suffix></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A14"><name><surname>Nakamura</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Heart Institute, S&#x000e3;o Paulo, Brazil</aff><aff id="I2"><label>2</label>Guy's and St Thomas' NHS Foundation Trust &#x00026; King's College London School of Medicine, London, UK</aff><pub-date pub-type="ppub"><year>2012</year></pub-date><pub-date pub-type="epub"><day>20</day><month>3</month><year>2012</year></pub-date><volume>16</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">32nd International Symposium on Intensive Care and Emergency Medicine</named-content></supplement><fpage>P438</fpage><lpage>P438</lpage><permissions><copyright-statement>Copyright &#x000a9;2012 Galas et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Galas et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://ccforum.com/content/16/S1/P438"/><conference><conf-date>20-23 March 2012</conf-date><conf-name>32nd International Symposium on Intensive Care and Emergency Medicine</conf-name><conf-loc>Brussels, Belgium</conf-loc></conference></article-meta></front><body><sec><title>Introduction</title><p>We compared hemostatic outcomes after treatment with fibrinogen concentrate or cryoprecipitate in pediatric cardiac surgery patients with intraoperative bleeding.</p></sec><sec sec-type="methods"><title>Methods</title><p>This was a single-center, randomized, open-label study. Key inclusion criteria were age &#x0003c;15 years, cardiac surgery involving cardiopulmonary bypass, intraoperative bleeding after neutralization of heparin, and hypofibrinogenemia. Patients received fibrinogen concentrate (60 mg/kg body weight; Haemocomplettan<sup>&#x000ae; </sup>P) or cryoprecipitate (10 ml/kg body weight). After study medication, allogeneic blood products were administered as required. Blood samples taken immediately before randomization and 1, 24 and 48 hours after study medication were subjected to laboratory and thromboelastometry (ROTEM) coagulation tests.</p></sec><sec sec-type="results"><title>Results</title><p>Sixty-three patients (fibrinogen concentrate: 30; cryoprecipitate: 33) completed the study. The median age was 3 years 5 months and the median weight was 6.7 kg. Median fibrinogen doses were 504 mg (fibrinogen concentrate) and 402 mg (cryoprecipitate). Plasma fibrinogen concentrations increased after study medication and were similar in the two groups. No significant between-group differences were observed in PT, aPTT or platelet count. In both groups, all ROTEM parameters showed significant improvement after study medication, with no clinically relevant between-group differences in any of the EXTEM, INTEM or FIBTEM clotting parameters. Total avoidance of allogeneic blood product transfusion was achieved in 70% of patients in the fibrinogen concentrate group versus 18.2% in the cryoprecipitate group (<italic>P </italic>&#x0003c; 0.001). The mean bleeding mass was significantly lower in the fibrinogen concentrate group than in the cryoprecipitate group after 30 minutes. The thorax was opened after study medication in zero patients (0%) in the fibrinogen concentrate group and in six patients (18.2%) in the cryoprecipitate group (<italic>P </italic>= 0.025).</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Fibrinogen concentrate raised fibrinogen levels and improved coagulation measures to a similar degree as cryoprecipitate. Bleeding and transfusion of allogeneic blood products were lower in the fibrinogen concentrate group. Fibrinogen concentrate may be a valuable option for controlling bleeding and avoiding transfusion in cardiac surgery.</p></sec></body></article>